BEYOND AIR INC

Company Overview

Beyond Air Inc. (Healthcare — Medical Devices) is a commercial-stage, IP-driven company that markets the LungFit® platform, an ionizer-based nitric oxide (NO) generator and delivery family. Its lead device, LungFit® PH, received FDA PMA (June 2022) and a CE mark (Nov 2024) and began U.S. commercialization; pipeline programs include LungFit PRO and GO plus affiliate programs Beyond Cancer (UNO intratumoral NO) and NeuroNOS. The company operates with a lean headcount (61 FTEs at Mar 31, 2025), relies on contract manufacturers and distributors, and reported FY2025 revenue of $3.7M but a net loss of $48.5M and cash of ~$6.9M, reflecting significant near‑term funding needs. Management cites sizable market potential (~$350M U.S., >$700M global for LungFit PH) but also material regulatory, reimbursement and manufacturing dependencies and Nasdaq bid‑price compliance risk.

Executive Compensation Practices

Compensation at this Medical Devices company is likely tied closely to commercialization and regulatory milestones (PMA/CE approvals, PMA supplements), hospital adoption metrics, sales growth, and clinical trial progress—metrics that directly drive revenue and reimbursement outcomes. As typical in the sector, executive pay will generally blend base salary, cash performance incentives (commercial/launch targets), and equity/option awards to align long‑term interests with product adoption; sales roles often have commission or incentive pay tied to hospital contracts. Company disclosures show a deliberate reduction in stock‑based compensation and a >30% headcount cut, indicating recent cost/retention tradeoffs and likely use of targeted equity grants for key hires or to conserve cash. Recent financings, warrants and royalty arrangements also dilute equity economics and can shift how long‑term equity incentives are structured (smaller grants, reloading features, or milestone‑based vesting).

Insider Trading Considerations

Beyond Air’s near‑term liquidity pressure (low cash balance, operating cash outflows, secured loan with warrants and royalty, ATM/shelf limits and recent equity financings) creates a higher likelihood of future dilutive financings and observable insider transactions tied to financing events. Insider activity may cluster around regulatory or commercial inflection points (FDA PMA supplements, CE/market launches, pivotal trial starts/results, reimbursement decisions) and seasonal demand cycles for respiratory disease, which can materially move the stock. Directors and executives who have participated in financings or advanced loans (noted $2.0M director financing, warrants in loan deals) may face conflicts of interest and should be watched for related‑party filings and timed trades; trades will also be subject to Section 16 reporting and typical blackout periods around earnings and material regulatory submissions, as well as potential Rule 10b5‑1 plan use.